Shamburg News · 8-K filed Oct 26, 2026, 6:00 AM EDT

Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at ESMO 2026

EIKN · Eikon Therapeutics, Inc.

  • Other event
  • Other
  • Materiality: medium

Eikon Therapeutics, Inc. presented updated data from its TeLuRide-005 trial of EIK1001 in combination with pembrolizumab and chemotherapy at the 2026 ESMO Congress on October 26, 2026. The efficacy-evaluable population (n=65) showed a 63.1% objective response rate and 89.2% disease control rate at the October 1, 2026 data cutoff. Grade 3 or higher treatment-related adverse events occurred in 48.6% of participants, and the Company expects a first interim analysis of its TeLuRide-008 trial in the second half of 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001193125-26-430860.

Written from the filing by Shamburg Markets. Figures are as reported by the company.